|
|
|
|
|
|
|
SIZE:
|
|
|
|
GENERIC NAME:
|
|
|
|
MANUFACTURER:
|
|
|
|
UNIT:
|
|
|
|
ADMINISTRATION ROUTE:
|
|
|
|
FDA PREGNANCY GROUP:
|
|
C
|
|
INDICATIONS:
|
|
Arthritis, rheumatoid |
|
Keratoconjunctivitis sicca |
|
Psoriasis |
|
Rejection, heart transplant, prophylaxis |
|
Rejection, liver transplant, prophylaxis |
|
Rejection, renal transplant, prophylaxis |
| |
|
|
SIDE EFFECTS:
|
|
Gingival hyperplasia |
|
hypertension |
|
nephrotoxicity |
|
Hepatotoxicity |
|
hypomagnesemia |
|
infection |
|
seizures |
|
vomiting |
|
Anaphylaxis |
|
hemolytic-uremic syndrome |
|
hyperkalemia |
|
pancreatitis |
|
paresthesia |
|
PTLD |
|
renal toxicity |
|
Hirsutism |
|
tremor |
|
Acne or oily skin |
|
gastrointestinal disturbances including abdominal discomfort, dyspepsia, and nausea |
|
headache |
|
leg cramps |
|
lethargy |
|
|
ABSOLUTE
CONTRAINDICATIONS :
|
|
|
|
RELATIVE
CONTRAINDICATIONS : |
|
>> Chickenpox, existing |
|
>> Herpes zoster |
|
>> Hepatic function impairment |
|
Hyperkalemia |
|
Hypertension |
|
>> Infection |
|
Malabsorption |
|
>> Renal function impairment |
|
|
ADULT DOSE:
|
|
Transplant rejection (prophylaxis) or
Transplant rejection (treatment)-Initial: Oral, 12 to 15 mg per kg of body weight a day beginning four to twelve hours before surgery and continuing for one to two weeks postoperatively, then reduced, usually by 5% a week, to the maintenance dose .
Maintenance: Oral, 5 to 10 mg per kg of body weight a day . |
|
MAXIMUM ADULT DOSE:
|
|
|
|
PEDIATRIC DOSE:
|
|
Transplant rejection (prophylaxis) or
Transplant rejection (treatment)-Initial: Oral, 12 to 15 mg per kg of body weight a day beginning four to twelve hours before surgery and continuing for one to two weeks postoperatively, then reduced, usually by 5% a week, to the maintenance dose .
Maintenance: Oral, 5 to 10 mg per kg of body weight a day .
Pediatric patients may require higher or more frequent dosing because of accelerated clearance . |
|
MAXIMUM PEDIATRIC
DOSE:
|
|
|
|
ELDERLY DOSE:
|
|
|
|
|
|
|
|